As a physician, I have witnessed countless medical breakthroughs that have transformed patient care and improved lives. One such innovation is the advent of GLP-1 agonists, a class of medications initially developed to treat type 2 diabetes but have since gained unprecedented popularity for their efficacy in weight loss.
These drugs, such as semaglutide, have garnered attention for their ability to help people shed significant amounts of weight, improve blood sugar control, and reduce the risk of cardiovascular disease.